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Abstract Myotonic dystrophy type 1 (DM1) is not char-
acterised by ataxia per se; however, DM1 and ataxia
patients show similar disturbances in movement coordi-
nation often experiencing walking and balance difficulties,
although caused by different underlying pathologies. This
study aims to investigate the use of a scale previously
described for the assessment and rating of ataxia (SARA)
with the hypothesis that it could have utility in DM1
patients as a measure of disease severity and risk of falling.
Data from 54 DM1 patients were pulled from the PHENO-
DM1 natural history study for analysis. Mean SARA score
in the DM1 population was 5.45 relative to the maximum
score of eight. A flooring effect (score 0) was observed in
mild cases within the sample. Inter-rater and test–retest
reliability was high with intraclass coefficients (ICC) of
0.983 and 1.00, respectively. Internal consistency was
acceptable as indicated by a Cronbach’s alpha of 0.761.
Component analysis revealed two principle components.
SARA correlated with: (1) all measures of muscle function
tested, including quantitative muscle testing of ankle dor-
siflexion (r = -0.584*), the 6 min walk test
(r = -0.739*), 10 m walk test (r = 0.741*), and the nine
hole peg test (r = 0.602*) and (2) measures of disease
severity/burden, such as MIRS (r = 0.718*), MDHI
(r = 0.483*), and DM1-Activ (r = -0.749*)
(*p\ 0.001). The SARA score was predicted by an
interaction between modal CTG repeat length and age at
sampling (r = 0.678, p = 0.003). A score of eight or
above predicted the use of a walking aid with a sensitivity
of 100% and a specificity of 85.7%. We suggest that further
research is warranted to ascertain whether SARA or com-
ponents of SARA are useful outcome measures for clinical
trials in DM1. As a tool, it can be used for gathering
information about disease severity/burden and helping to
identify patients in need of a walking aid, and can poten-
tially be applied in both research and healthcare settings.
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Introduction and objective
Myotonic dystrophy type 1 (DM1) is the most common
inherited neuromuscular disorder in adults affecting
approximately one in 8000 Caucasians worldwide [1].
DM1 is caused by an unstable expanded CTG repeat in the
DMPK gene that leads to a multi-systemic and clinically
heterogeneous disorder. Some of the most frequent clinical
features include: myotonia, progressive muscle weakness,
fatigue and daytime sleepiness, cardiac abnormalities, and
psycho-cognitive disturbances [1–4].
The size of the CTG expansion mutation impacts
directly on disease severity, progression, and age of onset.
The most common phenotype classification includes four
categories: mild (or late onset,[40 years); classic (adult,
11–40 years); childhood (early onset, 1–10 years); and
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congenital (severe,\1 year). However, there is no exact
threshold between these groups’ phenotype and genotype
[5–9].
A healthy neuromuscular system functions in a coordi-
nated manner to achieve a deliberate and smooth voluntary
movement; ataxia is a known lack of this controlled
coordination. The classic adult-onset ataxias share several
features with DM1, including slowly progressive gait dis-
turbance [10–13], dysarthria [2], abnormal motor control,
and reduced balance [12–14]. However, the classic ataxias
result as a consequence of cerebellar dysfunction, or a
damaged nervous system, whereas in DM1, these symp-
toms are most obviously caused by muscle weakness
[14, 15]. Besides the impact on daily life activities, a major
functional consequence and complication of these shared
ataxia-like features is falls [14–17].
A systematic assessment of ataxia-like symptoms in
patients with DM1, or in any other neuromuscular disease,
has not been previously assessed. However, assessing these
altered movement patterns in DM1 could give an indication
of the level of impairment and how this might be interfering
with the patient’s daily life, and possibly lead to a novel
measure of risk of falls as it has been for other diseases [18].
Other effective motor-performance assessment tools
have been proposed as outcome measures for DM1
[19, 20]. However, the practicability of these tests in
clinical practice is limited by the availability of evaluators
experienced with DM1, familiarity with the tests, time, and
clinic facilities. This study aims to test the scale for the
assessment and rating of ataxia (SARA), created by Sch-
mitz et al. [21, 22], with the overall aim of identifying and
validating SARA in measuring aspects of disease severity
in DM1 as a simple, and time-saving tool SARA has
already been identified as a reliable index of gait status and
daily live independence in ataxic stroke patients [18].
Methods
Sample
This study assessed data from 54 patients who had been
recruited into the ongoing PHENO-DM1 study (Myotonic
Dystrophy Type 1 Deep Phenotyping to Improve Delivery
of Personalized Medicine and Assist in the Planning,
Design and Recruitment of Clinical Trials) [23], a multi-
centre observational cohort study that aims to assess the
natural disease progression of DM1 and identify outcome
measures that efficiently represent the disease phenotype.
This cohort represents the first 54 patients recruited to one
of the sites (Royal Victoria Infirmary—Newcastle Upon
Tyne Hospitals NHS Foundation Trust). The inclusion
criteria for this study were: (1) 18 years or older; (2)
genetic confirmation of DM1; and (3) ability to consent and
participate throughout the entire study, including walking
tests (able to complete the 10 m walk test with no other
person’s assistance as a minimum requirement). Patients
were classified as mild if they met two of the three fol-
lowing criteria: (1) age of onset of 40 years or more; (2)
modal allele length of less than 200 CTG repeats; or (3) a
muscle impairment (MIRS) score of one or two [24].
Procedures
All the following tests and outcome measures come from
PHENO-DM1 study visits. The SARA test includes eight
performance-based items (gait, stance, sitting, speech dis-
turbance, finger chase, nose–finger test, fast alternating
hand movements, and heel-shin slide). Each item has an
independent scoring range, but applicable to all items a
score of zero implies no dysfunction, and an increasing
score represents a more severe degree of ataxia, acquiring
the maximum score if an individual is unable to complete
the item task at all. The scores for all items are summed,
and a score out of a maximum score of 40 is given. There is
no need of training or additional equipment for this
assessment [21]. However, for this study, assessors were
instructed to follow closely each item scoring system
regardless of the aetiology of the impairment.
Upon enrolment, all patients performed the SARA test
and were scored by one of three assessors, all of which had
previous experience with DM1 patients.
For assessment of reliability, 14 of the 54 patients were
rated twice by the same assessor at the beginning and once
at the end of the study visit. These 14 patients were also
independently assessed by a second assessor during the
day. The assessors were blinded as to each other’s results.
The main outcomes considered for comparisons were:
(1) muscle capacity (including quantitative muscle testing
(QMT) of hand-grip strength, knee extensors; hip flexors
and ankle dorsiflexors, plus the Muscular Impairment
Rating Scale (MIRS) [24]); (2) functional performance,
including: the nine hole peg test (9HPT); 6 min walk test
(6MWT); 30 s sit and stand (TSST); 10 m walk test
(10 MWT); and the 10 m walk/run test (10MW/RT); and
(3) patient reported outcome measures (PROM) which
included the DM1-Activa Rasch-built scale [25], which
assesses a patient’s performance in daily life activities and
the Myotonic Dystrophy Health Index (MDHI)b [26],
which scores the impact of a wide variety of disease related
signs and symptoms on a patient’s life.
Additional variables considered relevant for this analy-
sis were: (1) the estimated progenitor allele length (CTG
repeats) [27, 28], which were available for 26 (50%)
patients who have also been part of the OPTIMISTIC
cohort [29]c; (2) the use of a walking aid(s) when
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performing the functional tests; (3) patient’s reported
experienced falls over the last week, month, and year and
associated injuries (e.g., head injury, fracture, etc) for 24
patients; and (4) age at sampling.
This research is covered under the ethical approval of the
PHENO-DM1 study approved by The Newcastle and North
Tyneside Ethics committee (Reference: NE/15/0178)d.
Statistical analysis
Normal distribution was explored utilising the Shapiro–
Wilk test based on the size of this sample. Inter-rater and
test–retest reliability was expressed using intraclass corre-
lation coefficients (ICC) based on a two-way mixed-effect
model. Internal consistency was deemed acceptable with a
Cronbach’ alpha coefficient of 0.7 or higher [22]. A prin-
cipal component analysis was performed using varimax
rotation to extract components with eigenvalues above one.
Associations between SARA scores and other variables
were tested. Pearson’s and Spearman’s Rho correlation
tests were applied for normally and not normally dis-
tributed variables, respectively. An additional linear
regression test was performed in search of the square
R values to identify any causal relationship between vari-
ables. Construct validity was accepted when values fell
between the range of 0.4–0.8.
Receiver operating characteristic (ROC) curves were
constructed and based on the highest combination of sen-
sitivity and specificity to determine a cut-off point (if any)
that could differentiate the patient’s walking status (with or
without a walking assistive device). For all tests, p values of
\0.05 were considered statistically significant.
Results
Sample demographics
From the total cohort, three patients were excluded: two as
they were unable to complete the SARA due to physical
constraints (these patients were unable to lie flat during the
assessment of the heel-shin slide) and another one due to
comorbidity with Charcot–Marie Tooth disease. Leaving a
final sample of 51 patients (30 male) formed: of 10 mild
cases; 35 classic; and six considered early (childhood)
onset. Nine patients were using orthotics at visit and ten,
assistive devices (one side stick/cane) (Table 1).
SARA scoring
The mean SARA for this DM1 sample was 5.5 SD ± 4.5
(range 0–18.5). No patient scored a maximum score on any
of the scale items. Items sitting, finger chase, and nose
finger test ever scored between zero and two out of a
possible four, with ten patients scoring\1. There was a
statically significant difference in the mean (SD) SARA
scores between genders [female 3.8 (?3.1) vs. male 6.6
(±5) p\ 0.05] and phenotype groups [mild 2.5 (±2.2) vs.
classic 6.2 (±4.6) p\ 0.005].
Reliability
A two-way mixed-effect model determined the single
measures of the inter-rater and retest reliability with ICCs
of 0.916 and 1.0, respectively.
Validity
Cronbach alpha was acceptable at 0.761 for SARA score.
This was indicated to improve to 0.765 or 0.786 if the
finger chase or nose–finger test items were deleted,
respectively. Principal component analysis revealed two
components with an eigenvalue above one. The first
component had an eigenvalue of 3.36 and was responsible
for 42% of the variance present; it was also shown to affect
gait, stance, sitting, speech, and heel-shin slide (items
which represent more ataxia affecting balance and lower
limb function predominantly). The second component had
an eigenvalue of 1.61, responsible for 20.2% of total
variance and shown to affect items sitting, finger chase,
nose finger test, and heel-shin slide (items related to ataxia
affecting upper limb function) (Table 2).
Convergent validity
Muscle capacity assessment
SARA correlated significantly with all muscle strength
results, with the MIRS and the QMT ankle dorsiflexion as
the strongest (q of C0.5 at a significance of p\ 0.001).
Table 1 Sample demographics
Mean (SD) Range
(min to max)
Age (years) 47.7 (12.6) 18–77
Body mass index (kg/m2) 25.7 (6.8) 16.2–41.7
Time since disease onset (years) 19.5 (11.8) 5–53
MIRS (1–5) 3 (1.2)
1 = 12%
2 = 31%
3 = 18%
4 = 31%
5 = 8%
1–5
Modal CTG repeat length in blood 564.5a (324.9) 80–1130
a Only from those available
J Neurol (2017) 264:701–708 703
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The functional assessments (6MWT, 10MWT, 10MRT,
TSST, and 9HPT) also showed a strong and statistically
significant correlation score (Table 3). Assessments of
ambulation resulted in the highest square R values for the
SARA score.
Patient reported outcome measures (PROM)
The analysis showed a moderate-to-strong correlation for
both patient reported outcomes. The MDHI total score
produced a correlate of 0.48 and the DM1-Activ of -0.75,
both at a significance of p\ 0.0001 (Table 4).
Age and CTG repeat length
Surprisingly, there was no detectable correlation between
SARA and age at sampling (r = 0.131, p = 0.525). Like-
wise, there was only a marginally significant correlation
between SARA and modal CTG repeat length at sampling
(r = 0.377, p = 0.057). This most likely reflects antici-
pation mediated sampling bias with a highly significant
inverse correlation between age at sampling and modal
CTG repeat length (r = -0.528, p = 0.006). Indeed, there
was a highly significant interaction between age at sam-
pling and modal CTG repeat length (r = 0.678, p = 0.003)
accounting for *39% of the variation in SARA score
(adjusted r2 = 0.389).
Falls
Falls history of 24 patients was retrospectively collected,
and for this cohort, their SARA score correlated with
number of falls experienced in the previous month
(r = 0.436, p\ 0.05), but did not correlate with the
number of falls that had occurred in the last week or with
number of injuries as a result of falls.
Use of a walking aid
An ROC curve was generated for patients with and without
a walking aid during their walking tests based on SARA
score. The area under the curve was 0.962. An optimal
combination of sensitivity and specificity (100 and 85.7%,
respectively) gave a threshold SARA score of 8 or above
for the identification of DM1 patients in use of a walking
aid. With regard to the reported gait status in daily life
activities, the mean SARA scores for (1) totally indepen-
dent, (2) cane/crutch/walker dependent gait, and (3)
wheelchair (at least part-time dependent) ambulation were
3.9, 10, and 9.9, respectively, with a significant difference
between the independent gait mean scores against the
dependent (Fig. 1).
Discussion
SARA was originally intended and validated as an
assessment measure for patients with spinocerebellar
ataxia. Notably, average CTG repeat lengths in most
Table 2 Proportions of variance for each component within the items
of SARA
Item Component revealed
1 2
1 Gait 0.900
2 Stance 0.812
4 Speech 0.800
7 Fast alternating hand movement 0.632
8 Heel-shin slide 0.585 0.425
5 Finger chase 0.807
6 Nose–finger test 0.734
3 Sitting 0.487 0.631
Table 3 Correlations of SARA
scores with muscle function
tests: quantitative muscle test
(QMT), 6 min walk test
(6MWT), 30-s sit and stand test
(TSST), nine hole peg test
(9HPT), 10 m walk test
(10MWT), and the 10 m run test
(10MRT)
Measure Mean (SD) Correlation Linear regression Sig (p value)
R Adjusted square R
Hand-grip strength (kg) 14 (9.3) -0.505 0.239 \0.001
Wrist extension (lbs) 14.4 (9.7) -0.475 0.208 0.001
Ankle dorsiflexion (lbs) 19.3 (15.8) -0.584 0.324 \0.001
Knee extension (lbs) 47.8 (20.8) -0.308 0.085 0.023
Hip flexion (lbs) 29.0 (16.8) -0.184 0.004 0.367
6MWT (m) 442.5 (177.8) -0.739 0.472 \0.001
TSST (repetitions) 11.3 (6.1) -0.509 0.216 0.001
9HPT (s) 22.5 (10.6) 0.602 0.348 \0.000
10MWT (s) 8.6 (2.9) 0.741 0.539 \0.001
10MRT (s) 4.6 (3.3) 0.668 0.434 \0.001
MIRS (stages 1–5) 3.0 (1.2) 0.718 0.506 \0.001
704 J Neurol (2017) 264:701–708
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postmortem brain regions of DM1 patients are typically
thousands of repeats longer than the inherited allele length
and this very likely contributes to the wide range of neu-
rological symptoms observed in this disorder [30–32].
However, such large expansions are not observed in the
cerebellum, where the CTG repeat appears to be possibly
even more stable than observed in blood [30–32]. Of
course, this does not exclude a cerebellar dysfunction in
DM1, but it is not a frequent feature of myotonic dystro-
phy. This does not, however, mean that ataxia-like signs
are not present via the means of a different pathological
process (e.g., muscle weakness, impaired balance, or
intermittent myotonia) and that these cannot be measured
and quantified. Peripheral neuropathies could also be a
possible cause for alteration in SARA scoring; to assess
this formally nerve conduction studies would be required,
this is beyond the scope of this study. Furthermore, no
participants had brain MRI performed to look for evidence
of cerebral lesions. The present study aimed to investigate
the use of an ataxia scale, SARA, to measure these features
and the association of this score to disease burden.
The sample size used in this study was comparable to
previous validation studies of SARA in patients with ataxia
[18, 22]. The overall SARA scores for patients in this
sample were lower than those in the previous studies using
SARA. This can be attributed to the combination of the
sample containing ten mild cases, which tend to be unaf-
fected in terms of muscular impairment as displayed by a
ceiling effect within our results, and the exclusion of non-
ambulant DM1 patients who would have represented a
more severely affected group of patients. The generaliz-
ability of these results, therefore, may be limited to adult
patients still able to walk independently for at least ten
meters. However, this cohort represents a DM1 patient
subpopulation likely to be recruited into clinical trials.
The results of this study indicate good clinicometric
properties for the use of SARA in patients with DM1. Both
retest reliability and inter-rater reliability were very high
with similar scores to previous publications in other indi-
cations [18, 22]. However, the perfect ICC value of 1.00
for retest reliability may be attributed in part to the fact that
the repeat testing occurred on the same day with assessors
remembering their scores from earlier in the day. However,
after achieving a high inter-rater reliability in this study
and the proven reliability of SARA in other ataxia patients
in previous studies, we may consider SARA to be a reliable
and reproducible scale across different disease entities, not
limited to classical ataxias [22].
A good internal consistency was displayed, with a
Cronbach alpha score of 0.761. The change in Cronbach
alpha after removing either of the finger chase or nose
finger test items was negligible, and their inclusion in this
particular test may be valuable for two reasons. The first
being that the degree to which ataxia affects the upper
limbs will affect the degree of difficulty to which a patient
will find performing tasks, such as getting dressed, washing
themselves or cooking, etc., which ultimately will have an
effect on their quality of life. Second, effective coordina-
tion of upper limb movement provides a protective mech-
anism for patients when they fall (for example, patients
who outstretch an arm when [33] falling to the ground may
prevent the occurrence of significant injuries). Further
investigation on this topic is being considered and Rasch
analysis may improve the internal consistency of the scale
Table 4 Correlations of SARA
with the patient reported
outcomes: DM1-Activ Rasch-
built scale and Myotonic
Dystrophy Health Index
(MDHI)
PROM Mean (SD) Correlation Linear regression Sig (p value)
R Adjusted square R
MDHI—total 26.5 (21.1) 0.483 0.218 \0.001
MDHI—cognition 18.9 (19.4) 0.095 -0.012 0.51
MDHI—vision 15.6 (22.7) 0.056 -0.018 0.7
MDHI—myotonia 31.7 (29.0) 0.595 0.34 \0.001
MDHI—fatigue 42.2 (34.7) 0.435 0.172 0.002
MDHI—mobility 15.6 (30.3) 0.627 0.380 \0.001
DM1-Activ 2.74 (2.7) -0.749 0.552 \0.001
Fig. 1 SARA score according to gait status in daily life activities.
Values are mean (SD)
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for this particular population. However, any change or
adaptation of the scale would have an impact on the
comparability of the new datasets with historical control
and disease populations [34].
The component analysis identified two principal com-
ponents with an eigenvalue above one. It is difficult to
ascertain precisely what these components truly reflect, and
our speculation is based on the following observation. The
most prominent principal responsible for 42% of the vari-
ance seems to be derived from items affecting lower limbs
and general balance (i.e., gait, stance, sitting, and heel-shin
slide) as opposed to the second component which is solely
responsible for variance in the finger chase and nose–finger
tests which derives from upper limb function. It is unlikely
that either component is cerebellar ataxia as this would
likely be a component causing variance in all eight items as
opposed to a select number, but again, confirmatory testing,
such as neurophysiology or brain MRIs, would be required
to support this conclusion. We would suggest that both
these differing components are likely to be differing dis-
tributions of muscle weakness, because myotonic dystro-
phy is a heterogeneous disease and may affect patients
differently including the distribution of muscle weakness
[13, 15].
Ataxia is a clinical feature that has not been identified in
any form previously in patients with DM; however, the
authors predicted that the aetiology of these features of
impaired function and signs of imbalance in this condition
are at least in part a result of muscular weakness. Patient’s
with a higher SARA score performed significantly worse
on all tested measures of muscle function, including muscle
strength, balance, gait speed, and stamina. A significant
finding was the strong correlation of the SARA score with
ankle dorsiflexion strength as this muscle group that has
previously been linked significantly to falls risk in DM1
patients [14–17]. We did not attempt to cross-validate
SARA against other balance scores, such as the Berg bal-
ance score, the mini-BESTest, or the Step test for dynamic
balance [12, 14, 19, 20]. This would be recommended
before suggesting the application of SARA as a balance
score more broadly.
The impact that these motor signs can have in daily life
activities and disease burden was assessed with a correla-
tion test against DM1-Activ and MDHI reported outcomes
and both questionnaires showed a strong overall associa-
tion with the SARA total score. For the MDHI, the stron-
gest r values were for the sets related to mobility, when,
compared to the lack of correlation with the subscales of
vision and cognition, it gives signs of good discriminant
validity. The correlation of SARA to dependence level of
daily life activities has been shown before for ataxic stroke
patients [18].
As expected, SARA scores were highly positively cor-
related with age and CTG modal allele length. However,
these effects were only revealed in testing for an interaction
between these two factors. These data further highlight the
confounding effects of anticipation mediated age at sam-
pling ascertainment bias that results in sampling mildly
affected parents at a much older age relative to their more
severely affected offspring.
The analysis of predicted falls may be limited as this
was based on a retrospective interview of the most recent
week and month fall rate and not applicable to the whole
sample, which may be liable to recall bias. Moreover,
answers may have been influenced by the interviewer who
was not blinded to the SARA score. It is necessary to
follow this finding and search for confirmation with a
prospective longitudinal data recollection. However, sev-
eral variables showed strong correlation with SARA that
has previously been identified as fall predictors in DM1:
ankle dorsiflexion, knee extension and hip strength, and the
time to walk 10 m at a comfortable fast speed [14, 15, 17].
A prospective recollection of falls incidence previous to
their follow-up visit might corroborate the validity of these
results.
SARA is a clinical scale that corresponds well to
patient’s gait status and activities of daily living score [18]
assessing symptoms, such as gait performance, balance,
and movement coordination. In DM1, it could help to
identify patients with higher risk of falling and the
requirement of supplementary walking tools [18, 33]. We
used the ROC curve for patients with or without walking
aid against SARA score; a score of eight or above was used
to predict which patients were using an assistive device.
This score was selected as it achieved the highest combi-
nation of sensitivity and specificity possible (sensitivity
100% and specificity 85.7%). There were six patients with
SARA scores of eight or more with no records of an
assistive walking device during their visits. However, after
reviewing this cohort of six patients with the physiotherapy
team, we discovered that: two (33%) had experienced a
fracture as a result of a fall in the recent past and three
(50%) had been previously advised to use a walking aid
(for example, to use when walking longer distances). Kim
et al. [18] previously defined the following cut-off values to
identify the gait status on their ataxic cohort: scores of 8 or
lower for independent gait, 11.5 or lower for Q-cane gait,
and 12.25 or lower for walker assisted gait. Because of the
ambulatory conditions of this study’s cohort, the conclu-
sions for this topic have been limited to a cutoff that
identifies independent gait status from gait with assistive
device. Still, these results may highlight how SARA can be
considered by clinicians as a risk predictor, with a score of
eight or above as a guideline to implement a walking aid as
706 J Neurol (2017) 264:701–708
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a prophylactic intervention, hopefully preventing falls and
aiding in activities of daily living.
Summary
The present study aimed to investigate an ataxia scale in
patients with DM1, assessing its validity and reliability as a
possible tool for clinicians working with DM1 patients.
SARA could be a practical tool to assess disease severity,
falls risk, and the requirement of a walking aid in DM1.
SARA has met the criteria necessary to deem it reliable
and valid with high retest and inter-rater reliability, good
convergent validity, and acceptable internal consistency.
SARA has been shown to correlate with multiple gold
standard health outcome measures specific to patients with
DM1 (such DM1-Activ, MDHI) and markers of disease
severity. Furthermore, this study has revealed a SARA
score of eight or above that can predict the use of a walking
assistive device.
Future prospective research in a larger sample,
including other validated tests and assessments for falls,
followed by RASCH analysis, is warranted to further
explore the validity and utility of SARA or components
of SARA in DM1. Follow-up of these patients within the
PHENO-DM1 study at regular intervals will also help to
determine the sensitivity of SARA to detect disease
progression. It is unclear whether the scale can be used
in a wider range of neuromuscular diseases, children, or
older adults.
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